Section Arrow
VRTX.NASDAQ
- Vertex Pharmaceuticals
Quotes are at least 15-min delayed:2026/03/24 07:37 EDT
Pre Market
Last
 451
-0.235 (-0.05%)
Bid
450.02
Ask
469.44
High 452.94 
Low 450 
Volume 180 
Regular Hours (Closed)
Last
 451.235
-2.765 (-0.61%)
Day High 
463.7802 
Prev. Close
454 
1-M High
507.92 
Volume 
1.15M 
Bid
450.02
Ask
469.44
Day Low
450.97 
Open
458.42 
1-M Low
449.75 
Market Cap 
115.33B 
Currency 美元 
P/E 29.63 
%Yield -- 
10-SMA 469.21 
20-SMA 473.81 
50-SMA 469.18 
52-W High 513.975 
52-W Low 362.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
15.32/21.81
Enterprise Value
117.28B
Balance Sheet
Book Value Per Share
73.48
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
12.00B
Operating Revenue Per Share
38.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.21+0.0163+8.42%0.09PE
Pre Market 0.2012 -0.0088 -4.19%
GOSSGossamer Bio0.3732-0.0492-11.65%-- 
Pre Market 0.382 +0.0088 +2.36%
IBRXImmunityBio9.4+0.93+10.98%-- 
Pre Market 9.48 +0.08 +0.85%
AZTRAzitra0.2972+0.0144+5.09%-- 
Pre Market 0.2868 -0.0104 -3.50%
GERNGeron Corp1.54+0.08+5.48%-- 
Pre Market 1.54 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.